Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02148913 · ClinicalTrials.gov registry record · Phase 1
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Corewell Health West.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02148913: Completed Phase 1 study of Multiple Myeloma, sponsored by Corewell Health West.
NCT02148913 is a Phase 1 study of Multiple Myeloma that has completed, run by Corewell Health West. The registered enrollment target is 18 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02148913, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of melphalan and bendamustine in the setting of autologous transplantation for multiple myeloma is feasible and safe.
Primary Outcome
An absence of neutrophil engraftment by Day +22, absence of platelet engraftment by Day +35, and any grade 4 GI toxicity or any \>/= grade 3 non-hematologic toxicity as defined by the common toxicity criteria, which is deemed by the DSMB as probably related to the study protocol.
Conditions Studied
Interventions
- DRUG Cohort 1: Carfilzomib 15 mg/m2
- DRUG Cohort 2: Carfilzomib 20 mg/m2
- DRUG Cohort 2b: Carfilzomib 20 mg/m2
- DRUG Cohort 3b: Carfilzomib 27 mg/m2
Study Locations (1)
Michigan
- Spectrum Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
What the finished NCT02148913 record still lists
NCT02148913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Cohort 1: Carfilzomib 15 mg/m2 is the first listed.
NCT02148913 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02148913 about?
NCT02148913 is a clinical study titled "Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma". This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib. We hypothesize that the addition of carfilzomib to a conditioning regimen of melphalan and bendamustin...
What is the current status of trial NCT02148913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-06. Estimated completion is 2018-12.
What conditions does trial NCT02148913 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02148913?
The interventions under investigation include: Cohort 1: Carfilzomib 15 mg/m2 (DRUG), Cohort 2: Carfilzomib 20 mg/m2 (DRUG), Cohort 2b: Carfilzomib 20 mg/m2 (DRUG), Cohort 3b: Carfilzomib 27 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT02148913?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02148913 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02148913's enrollment target sits among peer trials
18 394th of 438 higher than 41 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia